Apellis Pharmaceuticals, Inc. - Special Call Transcript
Good morning, everyone, and welcome to the Apellis Pharmaceuticals, PEGASUS Top line Phase III Results Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Tracy Vineis, Vice President of Corporate Affairs at Apellis.
Good morning, everyone, and thank you for joining us today to discuss the top line results from the PEGASUS pivotal Phase III study, evaluating Pegcetacoplan or APL-2 in adults with Paroxysmal Nocturnal Hemoglobinuria or PNH. For those participating via conference call, we have made the slides available via webcast. A replay of this call will also be available on our website after the call. Before we begin, I would like to point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially.
I encourage you to consult the risk factors discussed in our SEC filings for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |